Vimta Labs Limited
Vimta Labs Limited is testing food and drugs. It also does contract research for clinical research and pre-clinical studies provider in India. It provides analytical, clinical and preclinical services to life sciences industries; quality and safety testing for food and beverage industries; and environment services to a wide spectrum of industries.
What Vimta files
- Others56
- Investor Meet46
- Board Meeting14
- PPTs10
- Updates9
- Dividend/Bonus8
Vimta Labs identified a cyber security incident impacting its IT infrastructure. Operations remain fully functional with no material impact reported. Experts are engaged for assessment, ensuring continued security focus.
Vimta Labs has paid a dividend of ₹2 per equity share to eligible shareholders. This action follows approval received at the company's Annual General Meeting, delivering on shareholder return commitments for the financial year.
Vimta Labs' shares held by APIDC are transferred to TSIDC due to state bifurcation. TSIDC is now classified as a 'Promoter - Body Corporate,' while APIDC moves to the 'Public' category, updating the shareholding structure.
Vimta Labs has announced a board meeting to approve the financial results for the quarter and half-year. Shareholders approved expanding into CDMO activities across drug discovery, biotech, pharmaceuticals, biopharma, and related sectors, along with increased focus on R&D in biologics, biosimilars, peptides, and complex generics. Remuneration for the MD and...
Q3 FY25 results show Vimta Labs Limited delivering total income of ₹911 Mn, marking a 21.1% year-on-year rise. The firm achieved a PAT of ₹175 Mn, translating to an impressive margin of 19.2%. EBITDA stood at ₹343 Mn with a robust margin of 37.6%, reflecting strong operational efficiency. For the...